Thursday Dec 5
Report: Sales of Antiretroviral Drugs for HIV Will Decrease Slightly Over Next Decade
Decision Resources, a research and advisory firm for pharmaceutical and health care issues, finds that major-market sales of antiretroviral drugs for human immunodeficiency virus infection will decrease marginally over the next decade, from an estimated $13.4 billion in 2012 to $13.1 billion in 2022 in the U.S., Europe, and Japan.
Sales of Antiretroviral Drugs for HIV Will Decrease Marginally Over...
Increasing availability of generics in cost-constrained markets will inhibit uptake of new, higher-priced agents and is responsible for decreased ARV sales in major pharmaceutical markets, particularly European markets where the impact of generic erosion will be the heaviest.
Entecavir + tenofovir works well for people with hepatitis B who have had prior treatment failure
A dual regimen of entecavir plus tenofovir for 48 weeks led to virological response and was generally well-tolerated among people with chronic hepatitis B who had experienced treatment failure with previous nucleoside/nucleotide analogue treatment, according to a poster presented earlier this month at The Liver Meeting 2013, the 64th annual meeting ... (more)
Chimerix: A Significant Player In The Antiviral Therapeutics Market
Viral diseases continue to pose some of the greatest challenges to modern medicine and therefore antiviral therapies are becoming an important, emerging area of pharmaceutical research.
Gilead Five-year Revenue Outlook, Part 1
Gilead is a large cap biotech company with a current market cap of $100 billion and $9.7B in sales in 2012.
HIV and Hepatitis
AASLD 2013: Entecavir + Tenofovir Works Well for Hepatitis B Patients with Prior Treatment Failure
A dual regimen of entecavir plus tenofovir for 48 weeks led to virological response and was generally well-tolerated as second-line therapy for chronic hepatitis B patients who had failed previous nucleoside/nucleotide treatment, according to a poster presentation at the 64th AASLD Liver Meeting last week in Washington, DC.